Stryker announced the U.S. commercial launch of Mako RPS for total knee replacement procedures on July 16, 2026. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery into a new category of orthopaedic robotics. The system combines robotic execution, intraoperative planning, and a familiar handheld power tool workflow to bring robotic technology to a new segment of the orthopaedic market.

The Mako RPS is designed to provide surgeons with an intuitive handheld robotic experience. It blends robotic execution with a familiar surgical experience, offering a new option for healthcare providers seeking flexibility in incorporating robotic technology. The system is compatible with Stryker's Triathlon Total Knee System and features a robotically enabled saw equipped with Stryker's patented active adjustment technology. This technology responds to a surgeon's hand movements and helps maintain alignment with the surgical plan in real time.

"Customer response during the limited market release has been exceptionally strong," said Keith Evans, VP/GM of Stryker's Mako and Enabling Technologies business. "As we expand the Mako portfolio, we're proud to set a new standard for what customers can expect from a handheld robotics technology – bringing together robotics, power tool expertise and a deep understanding of surgical workflows."

The system provides a familiar cutting experience without the need for cutting blocks. It offers an option for surgeons interested in adopting robotic technology while integrating easily into their existing surgical workflows. Mako RPS is built to work with Stryker's multi-specialty Q Guidance System, expanding the company's ecosystem of enabling technologies across the continuum of orthopaedic care.

"By combining robotic technology with the clinically proven Triathlon Total Knee System, Mako RPS delivers an intuitive surgical experience that builds on the implant and workflow familiarity surgeons know and trust," said Lisa Kloes, vice president and general manager of Stryker's Knee business.

BMO Capital has initiated coverage on Stryker (NYSE: SYK) with an Outperform rating and a price target of $369. This new endorsement comes alongside a revised outlook from Evercore ISI Group, which maintained its Outperform rating but adjusted its valuation expectations downward.

Evercore ISI Group analyst Vijay Kumar affirmed the Outperform rating on Stryker while lowering the price target to $350, down from the previous $355. The reduction reflects a revised assessment of the stock's potential, though the rating affirmation suggests continued confidence in the company's business fundamentals.

The new target from BMO Capital represents a more bullish entry point compared to the adjusted outlook from Evercore. The table below details the current ratings and price targets from both firms.

The consensus among analysts remains focused on Stryker's operational performance and market position. The varying price targets highlight different methodologies in valuing the medical technology company's future earnings and growth trajectory.